This HTML5 document contains 211 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00186/identifier/pubchem-compound/
n27http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n29http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n11http://linked.opendata.cz/resource/drugbank/dosage/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00186/identifier/kegg-drug/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00186/identifier/pubchem-substance/
n26http://www.drugs.com/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00186/identifier/drugbank/
n25http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB00186/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n10http://www.rxlist.com/cgi/generic/
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00186/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00186/identifier/chebi/
n28http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00186/identifier/pharmgkb/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00186/identifier/wikipedia/
n8http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00186
rdf:type
n3:Drug
n3:description
A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent. [PubChem]
n3:dosage
n11:271B54DF-363D-11E5-9242-09173F13E4C5 n11:271B54E0-363D-11E5-9242-09173F13E4C5 n11:271B54E1-363D-11E5-9242-09173F13E4C5 n11:271B54E2-363D-11E5-9242-09173F13E4C5 n11:271B54D8-363D-11E5-9242-09173F13E4C5 n11:271B54D9-363D-11E5-9242-09173F13E4C5 n11:271B54DA-363D-11E5-9242-09173F13E4C5 n11:271B54DD-363D-11E5-9242-09173F13E4C5 n11:271B54DE-363D-11E5-9242-09173F13E4C5 n11:271B54DB-363D-11E5-9242-09173F13E4C5 n11:271B54DC-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Kemper N, Poser W, Poser S: [Benzodiazepine dependence: addiction potential of the benzodiazepines is greater than previously assumed (author's transl)] Dtsch Med Wochenschr. 1980 Dec 5;105(49):1707-12. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7439058 # Lader M: Short-term versus long-term benzodiazepine therapy. Curr Med Res Opin. 1984;8 Suppl 4:120-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6144459 # Maltais F, Laberge F, Laviolette M: A randomized, double-blind, placebo-controlled study of lorazepam as premedication for bronchoscopy. Chest. 1996 May;109(5):1195-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8625666 # Heisterkamp DV, Cohen PJ: The effect of intravenous premedication with lorazepam (ativan), pentobarbitone or diazepam on recall. Br J Anaesth. 1975 Jan;47(1):79-81. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/238548 # Milligan DW, Howard MR, Judd A: Premedication with lorazepam before bone marrow biopsy. J Clin Pathol. 1987 Jun;40(6):696-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3611398 # FDA label
n3:group
approved
n3:halfLife
Parenteral administration = 14±5 hours; Oral administration = 2 hours.
n3:indication
For the management of anxiety disorders, and for treatment of status epilepticus.
n3:manufacturer
n4:271B54A3-363D-11E5-9242-09173F13E4C5 n4:271B54A0-363D-11E5-9242-09173F13E4C5 n4:271B54A1-363D-11E5-9242-09173F13E4C5 n4:271B549E-363D-11E5-9242-09173F13E4C5 n4:271B549F-363D-11E5-9242-09173F13E4C5 n4:271B549D-363D-11E5-9242-09173F13E4C5 n4:271B54B6-363D-11E5-9242-09173F13E4C5 n4:271B54B7-363D-11E5-9242-09173F13E4C5 n4:271B54B4-363D-11E5-9242-09173F13E4C5 n4:271B54B5-363D-11E5-9242-09173F13E4C5 n4:271B54B2-363D-11E5-9242-09173F13E4C5 n4:271B54B3-363D-11E5-9242-09173F13E4C5 n4:271B54B0-363D-11E5-9242-09173F13E4C5 n4:271B54B1-363D-11E5-9242-09173F13E4C5 n4:271B54AE-363D-11E5-9242-09173F13E4C5 n4:271B54AF-363D-11E5-9242-09173F13E4C5 n4:271B54AC-363D-11E5-9242-09173F13E4C5 n4:271B54AD-363D-11E5-9242-09173F13E4C5 n4:271B54AA-363D-11E5-9242-09173F13E4C5 n4:271B54AB-363D-11E5-9242-09173F13E4C5 n4:271B54A8-363D-11E5-9242-09173F13E4C5 n4:271B54A9-363D-11E5-9242-09173F13E4C5 n4:271B54BA-363D-11E5-9242-09173F13E4C5 n4:271B54BB-363D-11E5-9242-09173F13E4C5 n4:271B54B8-363D-11E5-9242-09173F13E4C5 n4:271B54B9-363D-11E5-9242-09173F13E4C5 n4:271B54A6-363D-11E5-9242-09173F13E4C5 n4:271B54A7-363D-11E5-9242-09173F13E4C5 n4:271B54A4-363D-11E5-9242-09173F13E4C5 n4:271B54A5-363D-11E5-9242-09173F13E4C5 n4:271B54A2-363D-11E5-9242-09173F13E4C5
owl:sameAs
n13:DB00186 n25:DB00186
dcterms:title
Lorazepam
adms:identifier
n15:46508468 n16:0054-3532-44 n17:3958 n18:D00365 n19:3821 n20:DB00186 n22:Lorazepam n23:52993 n24:PA450267
n3:mechanismOfAction
Lorazepam binds to an allosteric site on GABA-A receptors, which are pentameric ionotropic receptors in the CNS. Binding potentiates the effects of the inhibitory neurotransmitter GABA, which upon binding opens the chloride channel in the receptor, allowing chloride influx and causing hyperpolerization of the neuron.
n3:packager
n4:271B546B-363D-11E5-9242-09173F13E4C5 n4:271B546C-363D-11E5-9242-09173F13E4C5 n4:271B5469-363D-11E5-9242-09173F13E4C5 n4:271B546A-363D-11E5-9242-09173F13E4C5 n4:271B546F-363D-11E5-9242-09173F13E4C5 n4:271B5470-363D-11E5-9242-09173F13E4C5 n4:271B546D-363D-11E5-9242-09173F13E4C5 n4:271B546E-363D-11E5-9242-09173F13E4C5 n4:271B5473-363D-11E5-9242-09173F13E4C5 n4:271B5474-363D-11E5-9242-09173F13E4C5 n4:271B5471-363D-11E5-9242-09173F13E4C5 n4:271B5472-363D-11E5-9242-09173F13E4C5 n4:271B5477-363D-11E5-9242-09173F13E4C5 n4:271B5478-363D-11E5-9242-09173F13E4C5 n4:271B5475-363D-11E5-9242-09173F13E4C5 n4:271B5476-363D-11E5-9242-09173F13E4C5 n4:271B545B-363D-11E5-9242-09173F13E4C5 n4:271B545C-363D-11E5-9242-09173F13E4C5 n4:271B545F-363D-11E5-9242-09173F13E4C5 n4:271B5460-363D-11E5-9242-09173F13E4C5 n4:271B545D-363D-11E5-9242-09173F13E4C5 n4:271B545E-363D-11E5-9242-09173F13E4C5 n4:271B5463-363D-11E5-9242-09173F13E4C5 n4:271B5468-363D-11E5-9242-09173F13E4C5 n4:271B5461-363D-11E5-9242-09173F13E4C5 n4:271B5462-363D-11E5-9242-09173F13E4C5 n4:271B549A-363D-11E5-9242-09173F13E4C5 n4:271B549B-363D-11E5-9242-09173F13E4C5 n4:271B5489-363D-11E5-9242-09173F13E4C5 n4:271B5499-363D-11E5-9242-09173F13E4C5 n4:271B549C-363D-11E5-9242-09173F13E4C5 n4:271B547B-363D-11E5-9242-09173F13E4C5 n4:271B547C-363D-11E5-9242-09173F13E4C5 n4:271B5479-363D-11E5-9242-09173F13E4C5 n4:271B547A-363D-11E5-9242-09173F13E4C5 n4:271B547F-363D-11E5-9242-09173F13E4C5 n4:271B5480-363D-11E5-9242-09173F13E4C5 n4:271B547D-363D-11E5-9242-09173F13E4C5 n4:271B547E-363D-11E5-9242-09173F13E4C5 n4:271B5483-363D-11E5-9242-09173F13E4C5 n4:271B5484-363D-11E5-9242-09173F13E4C5 n4:271B5481-363D-11E5-9242-09173F13E4C5 n4:271B5482-363D-11E5-9242-09173F13E4C5 n4:271B5487-363D-11E5-9242-09173F13E4C5 n4:271B5488-363D-11E5-9242-09173F13E4C5 n4:271B5485-363D-11E5-9242-09173F13E4C5 n4:271B5486-363D-11E5-9242-09173F13E4C5 n4:271B5464-363D-11E5-9242-09173F13E4C5 n4:271B5497-363D-11E5-9242-09173F13E4C5 n4:271B5498-363D-11E5-9242-09173F13E4C5 n4:271B5467-363D-11E5-9242-09173F13E4C5 n4:271B548A-363D-11E5-9242-09173F13E4C5 n4:271B5465-363D-11E5-9242-09173F13E4C5 n4:271B5466-363D-11E5-9242-09173F13E4C5 n4:271B548D-363D-11E5-9242-09173F13E4C5 n4:271B548E-363D-11E5-9242-09173F13E4C5 n4:271B548B-363D-11E5-9242-09173F13E4C5 n4:271B548C-363D-11E5-9242-09173F13E4C5 n4:271B5491-363D-11E5-9242-09173F13E4C5 n4:271B5492-363D-11E5-9242-09173F13E4C5 n4:271B548F-363D-11E5-9242-09173F13E4C5 n4:271B5490-363D-11E5-9242-09173F13E4C5 n4:271B5495-363D-11E5-9242-09173F13E4C5 n4:271B5496-363D-11E5-9242-09173F13E4C5 n4:271B5493-363D-11E5-9242-09173F13E4C5 n4:271B5494-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
When a single 2 mg oral dose is give to healthy subjects, 88±4% of the administered dose was recovered in urine and 7±2% was recovered in feces. The percent of administered dose recovered in urine as lorazepam glucuronide was 74±4%. Only 0.3% of the dose was recovered as unchanged lorazepam, and the remainder of the radioactivity represented minor metabolites.
n3:synonym
Ativan Lormetazepam O-Chlorooxazepam Methyllorazepam O-Chloroxazepam (±)-Lorazepam N-Methyllorazepam
n3:toxicity
The most important clinical adverse event caused by lorazepam is respiratory depression. LD50, mouse, oral = 1850 mg/kg.
n3:volumeOfDistribution
1.3 L/kg. Unbound lorazepam can cross the blood-brain-barrier via passive diffusion.
n7:hasAHFSCode
n27:28-24-08
n3:foodInteraction
Take with food. Avoid alcohol. Avoid excessive quantities of coffee or tea (Caffeine).
n3:proteinBinding
91±2% bound to plasma proteins when given parenterally. When given orally, it is 85% bound to plasma proteins.
n3:synthesisReference
Igor Lifshitz, "Process for preparing pure crystalline lorazepam." U.S. Patent US20010039340, issued November 08, 2001.
n28:hasConcept
n29:M0012696
foaf:page
n10:loraz.htm n26:lorazepam.html
n3:IUPAC-Name
n5:271B54E7-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B54ED-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B54EC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B54E9-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B54EA-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B54EB-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B54E5-363D-11E5-9242-09173F13E4C5 n5:271B54FD-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B54E3-363D-11E5-9242-09173F13E4C5 n5:271B54E6-363D-11E5-9242-09173F13E4C5 n5:271B54FF-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B54E4-363D-11E5-9242-09173F13E4C5 n5:271B5500-363D-11E5-9242-09173F13E4C5
n3:pKa
n5:271B5501-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n8:N05BA06
n3:H-Bond-Acceptor-Count
n5:271B54F3-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B54F4-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B54EE-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B54EF-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B54F1-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B54F0-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B54F2-363D-11E5-9242-09173F13E4C5
n3:absorption
Readily absorbed with an absolute bioavailability of 90% when given orally. When intramuscularly administered, lorazepam is completely and rapidly absorbed. It achieves max serum concentration in 3 hours. The max serum concentration of a 4 mg dose is 48 ng/mL.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
846-49-1
n3:category
n3:clearance
Total clearance, parenteral administration = 1.1±0.4 mL/min/kg.
n3:containedIn
n6:271B54CD-363D-11E5-9242-09173F13E4C5 n6:271B54CE-363D-11E5-9242-09173F13E4C5 n6:271B54CB-363D-11E5-9242-09173F13E4C5 n6:271B54CC-363D-11E5-9242-09173F13E4C5 n6:271B54D1-363D-11E5-9242-09173F13E4C5 n6:271B54D2-363D-11E5-9242-09173F13E4C5 n6:271B54CF-363D-11E5-9242-09173F13E4C5 n6:271B54D0-363D-11E5-9242-09173F13E4C5 n6:271B54D5-363D-11E5-9242-09173F13E4C5 n6:271B54D6-363D-11E5-9242-09173F13E4C5 n6:271B54D3-363D-11E5-9242-09173F13E4C5 n6:271B54D4-363D-11E5-9242-09173F13E4C5 n6:271B54D7-363D-11E5-9242-09173F13E4C5 n6:271B54BD-363D-11E5-9242-09173F13E4C5 n6:271B54BE-363D-11E5-9242-09173F13E4C5 n6:271B54BC-363D-11E5-9242-09173F13E4C5 n6:271B54C1-363D-11E5-9242-09173F13E4C5 n6:271B54C2-363D-11E5-9242-09173F13E4C5 n6:271B54BF-363D-11E5-9242-09173F13E4C5 n6:271B54C0-363D-11E5-9242-09173F13E4C5 n6:271B54C5-363D-11E5-9242-09173F13E4C5 n6:271B54C6-363D-11E5-9242-09173F13E4C5 n6:271B54C3-363D-11E5-9242-09173F13E4C5 n6:271B54C4-363D-11E5-9242-09173F13E4C5 n6:271B54C9-363D-11E5-9242-09173F13E4C5 n6:271B54CA-363D-11E5-9242-09173F13E4C5 n6:271B54C7-363D-11E5-9242-09173F13E4C5 n6:271B54C8-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B54F9-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B54FB-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B54FC-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B54FE-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B54F8-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B54F7-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B54FA-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B54E8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B54F5-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B54F6-363D-11E5-9242-09173F13E4C5